The TYK2 pipeline: Data Byte

Astellas’ pan-JAK inhibitor Smyraf peficitinib may be the only marketed drug that hits TYK2, but several other selective TYK2 inhibitors are coming up behind, and they’re aiming to treat a diverse set of indications spanning autoimmune, inflammation, cancer and dermatology indications.

At least eight other small molecules targeting TYK2 are in preclinical or clinical development for a combined 17 indications...